{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Aspartate/alanine aminotransferase increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Nausea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Headache"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hyperhidrosis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Low platelet count"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Poor Graft Function (beyond 7 days post-mobilization)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Infusion-related toxicities are adverse events considered at least possibly-related to the study treatments MGTA-145, assessed from Baseline to 7 days after mobilization. The outcome is reported as a listing of the preferred terms for the \"at least possibly-related\" adverse events, with outcome being the number of adverse events of that preferred term. The outcome is a listing of numbers without dispersion.","groups":[{"description":"Number of adverse events by preferred term experienced by participants receiving MGTA-145 and Plerixafor","id":"OG000","title":"Number of Events"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"7 days after mobilization procedure","title":"Infusion-related Toxicities","type":"SECONDARY","unitOfMeasure":"adverse events"}